Table 2.

Univariate and multivariate Cox regression analysis of risk factors for recurrence

Univariate analysisMultivariable analysis
VariableHR (95% CI)PHR (95% CI)P
Age (≥50 vs. <50)1.036 (0.764–1.405)0.819
Sex (male vs. female)0.836 (0.546–1.280)0.41
HBV Infection (absent vs. present)0.968 (0.56–1.674)0.907
AFP (ng/mL) (<400 vs. ≥400)1.815 (1.336–2.466)0.000141.598 (1.163–2.196)0.004
Liver cirrhosis (absent vs. present)1.062 (0.754–1.496)0.731
Tumor multiplicity (single vs. multiple)1.866 (1.321–2.635)0.000401.811 (1.258–2.608)0.001
Maximal tumor size (cm; <5 vs. ≥5)1.337 (0.960–1.862)0.086
Tumor encapsulation (present vs. absent)1.667 (1.209–2.299)0.00181.322 (0.947–1.850)0.101
Edmondson grade (I/II vs. III/IV)1.428 (0.985–2.070)0.060
Pathologic TNM stage (I–II vs. III)1.807 (1.335–2.447)0.000131.092 (0.772–1.545)0.617
Portal vein thrombosis (absence vs. gross)1.864 (1.300–2.672)0.000711.621 (1.104–2.381)0.014
p-AMPK level (low vs. high)0.512 (0.352–0.745)0.000470.609 (0.409–0.906)0.014
Child-Pugh stage (A vs. B)1.190 (0.574–2.467)0.648
MELDa Score (<10 vs. ≥10)1.354 (0.653–2.807)0.434
  • aMELD (the model for end-stage liver disease). Significant results (P < 0.05) are given in bold.